Author: yourbiotech

Biotech startup Pandorum Technologies is raising $8 Mn (INR 64.8 Cr) in a fresh funding round from ace investor Ashish Kacholia, Everest Finance and Investment Company – the finance arm of Everest Foods, among others. The startup’s board of directors passed a resolution in the last week of December to raise the amount by allotting around 43,000 Series A 1 compulsorily convertible preference shares (CCPS). Of the proposed amount, the Bengaluru-based startup has already raised around $5.8 Mn (INR 48.8 Cr) from four investors – Kacholia, Everest Finance, Fastmover Advisory LLP, and Equipact Advisory LLP. The remaining amount is likely…

The UK is home to several biotech hubs, including the famous ‘golden triangle’, made up of Oxford, Cambridge, and London. In fact, after a $700 million surge in funding in the third quarter of 2023, the UK biotech scene is now one of the most vibrant in Europe, laying the foundation for numerous companies to develop innovative technologies, some of which have spun out of the nation’s most prestigious universities. In this article, we take a look at 16 UK biotech companies you should know.  Amphista Therapeutics Back to Top Amphista Therapeutics is focused on transforming the lives of patients with severe diseases, with a particular…

The House Select Committee on the Chinese Communist Party is planning to hold a field hearing on China biotech competition next week in Boston, Axios has learned. The big picture: Chinese genomics companies are becoming a national security concern in some quarters of Congress, where there’s bipartisan support for cutting off some firms from taxpayer funding. The details: The hearing on Monday will focus on U.S.-China competition in biotech, U.S. dependency on China for pharmaceuticals and Beijing’s biotech ambitions. The Boston area is a major biotech hub and also is the North American headquarters of BGI Group, the Chinese genomic sequencing behemoth that appears on the U.S.…

Rwandan-owned Akagera Medicines says it has secured over Rwf16.5 billion (€12 million), a round that is expected to allow for capacity-building, among other allocations. The development was announced on Saturday, February 4, by Michael Fairbanks, who is also the current Chairman of the Board of Akagera Medicines. The Rwanda Social Security Board (RSSB) is a majority share owner in the institution. ALSO READ: Akagera Medicines secures $1.5m to improve access Fairbanks was speaking to over 6,000 Rwandans and friends of Rwanda who had gathered in Washington DC for the eleventh edition of Rwanda Day. He disclosed the development during a panel…

With many exciting discoveries to make and new problems to solve, the biotechnology industry provides many career opportunities that could make a difference in people’s lives. So, if you are searching for a career in the field, we have listed five biotechnology careers that are currently in high demand, and likely still will be in the future.  Gene therapy researcherFrom genetics to virology, biotech researchers have contributed to some of the world’s most pioneering technological advances. As the name suggests, biotech researchers primarily conduct research. They often specialize in one particular area or type of work. Daily work might include…

A bill in the U.S. Congress that sparked a sell-off in shares of China’s WuXi AppTec hit a delay in the Senate this week, a Senate aide and three other sources said on Friday. The bill would prohibit federal agencies from contracting with China’s BGI Group, MGI, Complete Genomics, WuXi AppTec, their subsidiaries and other biotechnology companies of concern. It would also stop the government from entering into contracts with companies that use their equipment or services. It sent shares of Wuxi AppTec tumbling 21% overnight. The bill, sponsored by Democratic Senator Gary Peters, did not move out of committee…

Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage company focused on AI-powered immunotherapies, has announced the pricing of its public offering. The company is offering 3,750,000 American Depositary Shares (ADSs) and warrants to purchase an equivalent number of ADSs at a price of $4.00 each. The offering includes pre-funded warrants as an alternative to ADSs for certain investors. The warrants, exercisable immediately upon issuance at the same price of $4.00 per ADS, will expire five years from the date of issuance. Each ADS represents ten ordinary shares of Evaxion. The closing of the offering is anticipated around February 5, 2024, subject…

John Puisis was dubious when he first heard about the autoimmune science being developed by a coalition of scientists from Northwestern University and the University of Sydney. The group was developing a sort of Trojan horse that it hoped could be used to treat autoimmune diseases. They had developed polymer nanoparticles that could mimic dying cells, which the immune system won’t attack, but will naturally pull from the bloodstream and throw into the body’s waste collection and recycling systems — the spleen and liver — for disposal. Inside of the polymer nanoparticles, they could hide disease-specific antigen that could begin…

The German biotech ecosystem has evolved significantly over the years, marked by a complex interplay of scientific excellence and challenges in translating research into marketable products. Historically, the sector has seen limited access to capital, which has been a major obstacle in the commercialization of scientific breakthroughs. Despite these challenges, the German biotech landscape has seen biotech companies grow and become well-established entities and young promising companies make their entrance. This article delves into 13 biotech companies based in Germany that represent innovation and technological advancement in the field. From groundbreaking cancer treatments and pioneering mRNA technologies to novel approaches…

The US has extended its crackdown on Chinese companies to the new field of biotechnology, as a select committee of the US House of Representatives has drafted a bill to ban federally funded medical providers from entering into contracts with a group of Chinese biotech firms out of “national security” concerns. Analysts said on Monday that the systemic US actions abusing the concept of “national security” hinder normal bilateral economic and trade relations. They also called on Washington to correct its mistakes in a bid to boost normal cooperation between the Chinese and US business communities and promote faster sci-tech…